18F‑Pentixafor PET/MR and cardiac MRI to check heart microcirculation after a first heart attack
Official title: Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
Run by The Affiliated Hospital of Qingdao University · NCT07130409 · Data updated 2026-11-12
This will test whether 18F‑Pentixafor PET/MR plus cardiac MRI can reveal small‑vessel injury and recovery in people who had a first heart attack treated with emergency PCI.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | The Affiliated Hospital of Qingdao University Academic / other |
| Locations | 1 site (Qingdao, Shandong) |
| Status | Recruiting |
| Started | August 2025 |
| Main results expected | August 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 19, 2025 |
| Trial ID | NCT07130409 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a first‑time acute myocardial infarction who received emergency PCI, have complete baseline data, and can safely undergo MRI are ideal candidates.
✕Probably not a fit
Patients with prior myocardial infarction or coronary revascularization, severe unstable cardiac or systemic disease, or contraindications to MRI are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort will enroll 20 patients with a first acute myocardial infarction who underwent emergency PCI at The Affiliated Hospital of Qingdao University. Participants will receive baseline cardiac MRI within 7 days after PCI, an 18F‑Pentixafor PET/MR examination, routine laboratory tests and ECG, and a follow-up cardiac MRI at six months. Imaging will be read blindly by at least two specialist physicians in radiology and nuclear medicine, and clinical, laboratory, and imaging data will be integrated to characterize coronary microcirculatory function and myocardial recovery. The protocol is observational and does not assign investigational treatments.
Why it matters
Potential benefit: If successful, this imaging approach could help clinicians detect microvascular damage earlier and better predict heart recovery after a heart attack.
How similar studies have gone: Small prior studies using CXCR4‑targeted tracers such as 18F‑Pentixafor in post‑infarction imaging have shown promising signals, but broader clinical validation remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure. Exclusion Criteria: * Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions. Patients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural/functional assessments. Prior history of myocardial infarction, coronary revascularization (PCI/CABG). Concurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic/autoimmune diseases, or severe hepatic/renal failure. Contraindications to CMR (claustrophobia, pacemaker implantation, etc.). Pregnant, breastfeeding, or women of childbearing potential without effective contraception. Sexually active individuals of reproductive age unwilling to use reliable contraception.
Where it's running
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China Recruiting
Study contacts
- Study coordinator: Pei Nie, MD
- Email: niepei@qdu.edu.cn
- Phone: 0532-82911500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can 1-Hz rTMS help with heart rhythm and inflammation after a heart attack?
This trial tests whether daily 1-Hz repetitive transcranial magnetic stimulation can improve heart rate variability and reduce inflammation in people who have had an acute myocardial infarction, compared with a sham procedure.
-
Trends and risk factors for adverse events after primary PCI in AMI patients over 20 years
This study looks at real-world AMI patients who had a primary PCI to see how often serious events happen during a 2-year follow-up and what factors predict them.
-
SPIKE FLOW endocardial pacing lead safety and performance study
This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.
-
Predict Arrhythmia Risk with Intelligent Software
Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
BRIDGE: Embedding consumer mHealth tools into cardiac rehab
This study tests whether adding a mobile health tool to standard center-based cardiac rehab helps heart patients stay active and follow healthy habits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.